Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on antibody-based oncology therapeutics, pursuing novel immune-activating therapies targeting cancer. The company reached the public markets through a SPAC combination, with this Form 8-K, filed February 2, 2021 and carrying accession number 0001213900-21-006227, representing an early disclosure event tied to that transaction process. Operating in the healthcare and biotechnology sector, Apexigen submitted this filing during a particularly active period for SPAC activity in the biopharmaceutical space. The company subsequently traded under the APGN ticker on Nasdaq following completion of its de-SPAC process. Sign up at SpacDesk for the full deal profile, sponsor details, and comparable transaction data on APGN.